Volume 19 Issue 10, October 2020

Volume 19 Issue 10

Ligands as drug targets, inspired by the Review on p695.

Cover design: Susanne Harris.

Comment

  • Comment |

    The response to the COVID-19 pandemic has shown that exceptional efforts can dramatically accelerate the clinical development of vaccines. We propose that it is time to also take immediate actions to improve clinical trials in other areas to better serve all patients.

    • Rod MacKenzie
    • , Peter Honig
    • , Judy Sewards
    • , Robert Goodwin
    •  & Marie-Pierre Hellio

News & Analysis

  • News |

    Sanofi and others are testing whether trispecific antibodies might have applications in cancer and infectious disease indications.

    • Asher Mullard
  • News in Brief

  • Biobusiness Briefs

  • An Audience With

  • An Audience With |

    Computational chemistry is already embedded in the drug discovery process. Schrödinger — a company that was founded more than 30 years ago to develop chemical simulation software for biopharmaceutical partners — believes that it should be more foundational still. Having co-founded several biotechs in the past decade, including Nimbus Therapeutics and Morphic Therapeutics, Schrödinger launched its own drug discovery pipeline in 2018 to expand this model. Heading up that effort is Schrödinger Chief Biomedical Scientist Karen Akinsanya. A pharmacologist by training, Akinsanya has more than 20 years industry experience working at the bench, the bedside and then in the boardroom. She now goes back to her research roots, leading the screening of hundreds of billions of compounds against targets of interest. She spoke with Asher Mullard about Schrödinger’s physics-based approach to computational chemistry, the bottlenecks in this approach, and the new opportunities it can open up.

    • Asher Mullard
  • From the Analyst's Couch

Research Highlights

Reviews

  • Review Article |

    Oligonucleotide-based drugs have the potential to treat or manage a wide range of diseases. However, the widespread application of such therapies has been hampered by the difficulty in achieving efficient delivery to extrahepatic tissues. Here, Roberts et al. overview oligonucleotide-based drug platforms and assess approaches being employed to improve their delivery.

    • Thomas C. Roberts
    • , Robert Langer
    •  & Matthew J. A. Wood
  • Review Article |

    With the rise of antibody-based therapies in the past two decades, soluble protein ligands such as inflammatory cytokines have become an increasingly important class of drug targets. This Review analyses drugs targeting ligands that have reached clinical development in the past three decades and discusses strategic issues such as the pros and cons of different ligand-targeting therapeutic modalities.

    • Misty M. Attwood
    • , Jörgen Jonsson
    • , Mathias Rask-Andersen
    •  & Helgi B. Schiöth
  • Review Article |

    Several poly(ADP-ribose) polymerase (PARP) inhibitors have now been approved as treatments for various types of cancer. In this Review, Curtin and Szabo discuss the history of the development of PARP inhibitors and progress in their use for cancer therapy, as well as the potential for repurposing PARP inhibitors for the treatment of non-oncological diseases such as stroke.

    • Nicola J. Curtin
    •  & Csaba Szabo

Search